Actelion's heart-lung drug meets main goal in late-stage study

[riky]

Actelion's heart-lung drug meets main goal in late-stage study

Actelion Ltd said its experimental heart and lung drug Selexipag met its primary goal in a late-stage study, giving the Swiss biotech company a potential second big seller to replenish its product pipeline. Results of the Phase III study involving 1,156 patients found that Selexipag reduced the risk of a morbidity/mortality event by 39 percent versus a placebo in patients suffering from pulmonary arterial hypertension (PAH). Selexipag is the third drug from Actelion to treat PAH, a progressively worsening condition characterised by abnormally high blood pressure in the arteries of the lungs. The positive data is a boost to Europe's biggest biotech company and should help reassure investors that the firm's long-term growth prospects are on course, after another PAH treatment, Opsumit, won approval in Europe and the United States.

Source: You are not allowed to view links. Register or Login